-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Dyne Therapeutics (NASDAQ:DYN) Trading 4.6% Higher on Analyst Upgrade
Dyne Therapeutics (NASDAQ:DYN) Trading 4.6% Higher on Analyst Upgrade
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) shares traded up 4.6% on Wednesday after Piper Sandler raised their price target on the stock from $17.00 to $23.00. The stock traded as high as $12.21 and last traded at $12.21. 100 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 226,386 shares. The stock had previously closed at $11.67.
Several other research firms also recently weighed in on DYN. Raymond James assumed coverage on shares of Dyne Therapeutics in a research report on Monday, July 11th. They issued an "outperform" rating and a $15.00 target price for the company. Chardan Capital assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, July 20th. They set a "buy" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.00.
Get Dyne Therapeutics alerts:Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. Deep Track Capital LP acquired a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $27,255,000. Franklin Resources Inc. lifted its stake in shares of Dyne Therapeutics by 48.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,746,481 shares of the company's stock worth $11,999,000 after acquiring an additional 568,533 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Dyne Therapeutics by 51.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,254,800 shares of the company's stock worth $14,920,000 after acquiring an additional 427,800 shares during the period. Woodline Partners LP lifted its stake in shares of Dyne Therapeutics by 58.0% in the 1st quarter. Woodline Partners LP now owns 813,139 shares of the company's stock worth $7,839,000 after acquiring an additional 298,538 shares during the period. Finally, Monashee Investment Management LLC lifted its stake in Dyne Therapeutics by 193.5% during the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock valued at $2,696,000 after purchasing an additional 184,404 shares during the last quarter. 90.22% of the stock is owned by institutional investors and hedge funds.
Dyne Therapeutics Stock Up 18.3 %
The firm has a market capitalization of $714.36 million, a price-to-earnings ratio of -3.91 and a beta of 0.70. The firm's 50 day moving average is $11.17 and its 200 day moving average is $8.25.Dyne Therapeutics (NASDAQ:DYN – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.22). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current year.
About Dyne Therapeutics
(Get Rating)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) shares traded up 4.6% on Wednesday after Piper Sandler raised their price target on the stock from $17.00 to $23.00. The stock traded as high as $12.21 and last traded at $12.21. 100 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 226,386 shares. The stock had previously closed at $11.67.
戴恩治療公司(納斯達克代碼:DYN-GET評級)股價週三上漲4.6%,此前派珀·桑德勒將該股目標價從17.00美元上調至23.00美元。該股盤中一度漲至12.21美元,最新報12.21美元。午盤成交量為100股,較226,386股的日均成交量下降100%。該股此前收盤價為11.67美元。
Several other research firms also recently weighed in on DYN. Raymond James assumed coverage on shares of Dyne Therapeutics in a research report on Monday, July 11th. They issued an "outperform" rating and a $15.00 target price for the company. Chardan Capital assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, July 20th. They set a "buy" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.00.
其他幾家研究公司最近也加入了對Dyn的看法。雷蒙德·詹姆斯在7月11日星期一的一份研究報告中對戴恩治療公司的股票進行了報道。他們對該公司的評級為“跑贏大盤”,目標價為15.00美元。查丹資本在7月20日星期三的一份研究報告中承擔了對戴恩治療公司股票的報道。他們為該公司設定了“買入”評級和17.00美元的目標價。一名分析師對該股的評級為賣出,四名分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的平均評級為“中等買入”,平均目標價為21.00美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. Deep Track Capital LP acquired a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $27,255,000. Franklin Resources Inc. lifted its stake in shares of Dyne Therapeutics by 48.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,746,481 shares of the company's stock worth $11,999,000 after acquiring an additional 568,533 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Dyne Therapeutics by 51.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,254,800 shares of the company's stock worth $14,920,000 after acquiring an additional 427,800 shares during the period. Woodline Partners LP lifted its stake in shares of Dyne Therapeutics by 58.0% in the 1st quarter. Woodline Partners LP now owns 813,139 shares of the company's stock worth $7,839,000 after acquiring an additional 298,538 shares during the period. Finally, Monashee Investment Management LLC lifted its stake in Dyne Therapeutics by 193.5% during the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock valued at $2,696,000 after purchasing an additional 184,404 shares during the last quarter. 90.22% of the stock is owned by institutional investors and hedge funds.
一些對衝基金和其他機構投資者最近買賣了Dyn的股票。Deep Track Capital LP在第四季度收購了戴恩治療公司的新股份,價值約27,255,000美元。富蘭克林資源公司(Franklin Resources Inc.)在第二季度增持了戴恩治療公司48.3%的股份。富蘭克林資源公司在此期間增持了568,533股,目前持有1,746,481股該公司股票,價值11,999,000美元。Point72 Asset Management L.P.在第四季度增持了Dye Treateutics的股份51.7%。Point72 Asset Management L.P.在此期間額外收購了427,800股,現在擁有1,254,800股該公司股票,價值14,920,000美元。Woodline Partners LP在第一季度增持了Dye Treateutics 58.0%的股份。在此期間增持了298,538股後,Woodline Partners LP現在擁有813,139股該公司的股票,價值7,839,000美元。最後,Monashee Investment Management LLC在第一季度將其在戴恩治療公司的股份增加了193.5%。Monashee Investment Management LLC在上個季度額外購買了184,404股後,現在擁有279,704股該公司股票,價值2,696,000美元。90.22%的股票由機構投資者和對衝基金持有。
Dyne Therapeutics Stock Up 18.3 %
戴恩治療公司股票上漲18.3%
Dyne Therapeutics (NASDAQ:DYN – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.22). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current year.
戴恩治療公司(納斯達克:DYN-GET評級)最近一次公佈收益結果是在8月4日星期四。該公司公佈本季度每股收益(1.01美元),低於(0.79美元)和(0.22美元)的普遍預期。賣方分析師平均預測,戴恩治療公司本年度的每股收益將達到3.59美元。
About Dyne Therapeutics
戴恩治療公司簡介
(Get Rating)
(獲取評級)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
戴恩治療公司是一家肌肉疾病公司,作為一家生物技術公司,專注於在美國推進遺傳驅動的肌肉疾病的治療。它利用其提供疾病修正療法的FORCE平臺,為強直性肌營養不良1型、Duchenne肌營養不良和麪肩肩關節營養不良以及罕見的骨骼肌、心臟和代謝性肌肉疾病開發各種計劃。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
- 免費獲取StockNews.com關於戴恩治療公司(Dyn)的研究報告
- 3家高利潤率芯片製造商勢必復甦
- 將受益於拜登關税假期的3只太陽能股
- REV集團在電動汽車世界擁有深厚的護城河
- G-III服裝集團有限公司是價值陷阱嗎?
- 美國銀行看好這兩隻歐洲酒類股票
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《戴恩治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收對戴恩治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧